Prostate cancer is a heterogeneous and prevalent disease. We need to know in greater depth the molecular biology of this type of tumors in order to develop new drugs that improve survival in our patients as well as to know who will benefit most from existing treatments. The objective of our abstract is to describe the design, workflow and start-up of the collaborative CAPPRICE project: “Clinical and molecular characterization study of Advanced Prostate Cancer patients in la Princesa University Hospital”.
The CAPPRICE project is an observational, retrospective, cohort database study, aimed to describe the profile and proportion of germline and/or somatic mutations across the genome, using a customized DDR panel to study key genes (Table), in patients with metastatic castration resistant prostate cancer (mCRPC). Clinical management and outcomes data from patients with available tissue samples and analysed gene mutation status with whole exome or targeted sequencing will be analysed in this study in three timeline cohorts: mCRPC, metastatic castration sensitive prostate cancer (mCSPC) and localized prostate cancer (LPC). The study was approved by the local Ethics Committee.
Gene Gene type BRCA2 DNA HR repair BRCA1 PTEN Cell signaling ATM DNA damage sensor CDK12 DNA repair/Transcription regulation MSH2 Mismatch DNA repair MSH6 MLH1 PSM2 PIK3CA Cell signaling PIK3CB AKT1 PALB2 DNA HR repair BARD1 RAD54L FANCL RAD51D RAD51B CHEK2 DNA repair BRIP1 DNA HR repair FANCA NBN RAD51C CHEK1 DNA repair AR Androgen signaling TP53 Apoptosis MYC Cell cycle RB1 HDAC2 epigenetic/DNA repair APC Wnt pathway CTNNB1 PIK3R1 Cell Signaling EZH2 Epigenetic/NE PCa AURKA Cell cycle MYCN Cell plasticity/NE PCa IDH1 Mitochondrial metabolism IDH2 KMT2D Epigenetic chromatin reg CHD1 Transcriptional regulation HOXB13 Transcription factor SPOP Taxonomic/Ubiquitin
We first established a functional working group among the research departments (urology, medical oncology, radiation oncology and pathology) responsible for the coordination, database elaboration, and patients screening. The pathological samples were reviewed to ensure the necessary sample to perform the analysis. In cases without enough tissue, a blood sample from living patients was extracted with prior informed consent to perform germline analysis. A total of 136 patients have met the inclusion criteria and the genetic analysis is currently being carried out. Finally, an outcome analysis plan was designed throughout the mCRPC, mCSPC and LPC cohorts, including only variables and outcomes relevant for that particular cohort.
Teamwork in a multidisciplinary approach is essential for an efficient and comprehensive translational evaluation in prostate cancer research and better understanding the prognosis and treatment of PC patients.
The authors.
Has not received any funding.
All authors have declared no conflicts of interest.